Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 652,576,896
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.41
  • Price/Sales 19.00
  • Price/Cash Flow 47.41
  • Price/Book 44.48
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 26.13% ( +0.22%)
  • Historical Volatility 20.68%
  • IV Percentile 22%
  • IV Rank 15.18%
  • IV High 44.88% on 08/03/23
  • IV Low 22.77% on 08/11/23
  • Put/Call Vol Ratio 0.46
  • Today's Volume 31,501
  • Volume Avg (30-Day) 23,147
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 239,943
  • Open Int (30-Day) 259,884

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.81
  • Number of Estimates 4
  • High Estimate 0.82
  • Low Estimate 0.79
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.68 +6.96%
on 06/03/24
148.15 -3.49%
on 06/25/24
+7.70 (+5.69%)
since 05/31/24
3-Month
121.29 +17.88%
on 05/03/24
148.15 -3.49%
on 06/25/24
+16.52 (+13.06%)
since 04/02/24
52-Week
75.56 +89.23%
on 07/11/23
148.15 -3.49%
on 06/25/24
+62.06 (+76.70%)
since 06/30/23

Most Recent Stories

More News
Why Novo Nordisk Stock Is Slipping Today

President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people."

LLY : 906.71 (-0.84%)
NVO : 142.98 (-1.68%)
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.

Wegovy was just approved in China.

NVO : 142.98 (-1.68%)
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy

The market for weight loss medicines keeps getting hotter and hotter.

ALT : 6.74 (-6.39%)
NVO : 142.98 (-1.68%)
This Is Massive News for Eli Lilly Investors

A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.

NVO : 142.98 (-1.68%)
BIIB : 228.82 (-1.27%)
LLY : 906.71 (-0.84%)
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.

Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector.

NVO : 142.98 (-1.68%)
NVDA : 122.67 (-1.31%)
LLY : 906.71 (-0.84%)
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

These healthcare stocks have clear paths to growth over the next few years.

LLY : 906.71 (-0.84%)
NVO : 142.98 (-1.68%)
VRTX : 473.78 (+0.54%)
VKTX : 51.54 (-6.83%)
TMDX : 148.97 (-0.81%)
1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult...

NVO : 142.98 (-1.68%)
CTLT : 56.20 (+0.07%)
Better Growth Stock: Archer Aviation or Viking Therapeutics?

Which one of these potential disruptors is the better buy?

LLY : 906.71 (-0.84%)
NVO : 142.98 (-1.68%)
ACHR : 3.72 (+8.77%)
VKTX : 51.54 (-6.83%)
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?

This is a matchup that the latecomer might not be able to win.

PFE : 27.83 (-1.38%)
NVO : 142.98 (-1.68%)
Novo Nordisk’s Weight Loss Drug Approved In China

Novo Nordisk’s (NVO) weight loss drug “Wegovy” has been approved in China, opening a huge new market ...

NVO : 142.98 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 148.90
2nd Resistance Point 146.13
1st Resistance Point 144.56
Last Price 142.98
1st Support Level 140.22
2nd Support Level 137.45
3rd Support Level 135.88

See More

52-Week High 148.15
Last Price 142.98
Fibonacci 61.8% 120.42
Fibonacci 50% 111.85
Fibonacci 38.2% 103.29
52-Week Low 75.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar